Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer

Masayuki Takeda1, Isamu Okamoto1, Yasumasa Nishimura2, Kazuhiko Nakagawa11Department of Medical Oncology, 2Department of Radiation Oncology, Kinki University Faculty of Medicine, Osaka, JapanAbstract: The epidermal growth factor receptor (EGFR) is a promising therapeutic target in non-small cell lun...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Takeda M, Okamoto I, Nishimura Y, Nakagawa K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/44aca92e361a49af894d9a642d375a3d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:44aca92e361a49af894d9a642d375a3d
record_format	dspace
spelling	oai:doaj.org-article:44aca92e361a49af894d9a642d375a3d2021-12-02T07:35:33ZNimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer1179-2728https://doaj.org/article/44aca92e361a49af894d9a642d375a3d2011-10-01T00:00:00Zhttp://www.dovepress.com/nimotuzumab-a-novel-monoclonal-antibody-to-the-epidermal-growth-factor-a8470https://doaj.org/toc/1179-2728Masayuki Takeda1, Isamu Okamoto1, Yasumasa Nishimura2, Kazuhiko Nakagawa11Department of Medical Oncology, 2Department of Radiation Oncology, Kinki University Faculty of Medicine, Osaka, JapanAbstract: The epidermal growth factor receptor (EGFR) is a promising therapeutic target in non-small cell lung cancer, and several therapeutic agents that target this receptor, including EGFR tyrosine kinase inhibitors and monoclonal antibodies to EGFR, have been developed. Such monoclonal antibodies have shown efficacy in combination with chemotherapy and radiotherapy. Nimotuzumab (h-R3) is a humanized monoclonal antibody to EGFR, and its effects in combination with radiation have been sufficiently promising to warrant further investigation in several types of cancer. Furthermore, the typical severe dermatologic toxicities associated with other monoclonal antibodies to EGFR have not been observed with nimotuzumab. We here summarize the results of preclinical studies as well as of previous and ongoing clinical trials of nimotuzumab for the treatment of non-small cell lung cancer.Keywords: non-small cell lung cancer, epidermal growth factor receptor, antibodyTakeda MOkamoto INishimura YNakagawa KDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol 2011, Iss default, Pp 59-67 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Takeda M Okamoto I Nishimura Y Nakagawa K Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer
description	Masayuki Takeda1, Isamu Okamoto1, Yasumasa Nishimura2, Kazuhiko Nakagawa11Department of Medical Oncology, 2Department of Radiation Oncology, Kinki University Faculty of Medicine, Osaka, JapanAbstract: The epidermal growth factor receptor (EGFR) is a promising therapeutic target in non-small cell lung cancer, and several therapeutic agents that target this receptor, including EGFR tyrosine kinase inhibitors and monoclonal antibodies to EGFR, have been developed. Such monoclonal antibodies have shown efficacy in combination with chemotherapy and radiotherapy. Nimotuzumab (h-R3) is a humanized monoclonal antibody to EGFR, and its effects in combination with radiation have been sufficiently promising to warrant further investigation in several types of cancer. Furthermore, the typical severe dermatologic toxicities associated with other monoclonal antibodies to EGFR have not been observed with nimotuzumab. We here summarize the results of preclinical studies as well as of previous and ongoing clinical trials of nimotuzumab for the treatment of non-small cell lung cancer.Keywords: non-small cell lung cancer, epidermal growth factor receptor, antibody
format	article
author	Takeda M Okamoto I Nishimura Y Nakagawa K
author_facet	Takeda M Okamoto I Nishimura Y Nakagawa K
author_sort	Takeda M
title	Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer
title_short	Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer
title_full	Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer
title_fullStr	Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer
title_full_unstemmed	Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer
title_sort	nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/44aca92e361a49af894d9a642d375a3d
work_keys_str_mv	AT takedam nimotuzumabanovelmonoclonalantibodytotheepidermalgrowthfactorreceptorinthetreatmentofnonsmallcelllungcancer AT okamotoi nimotuzumabanovelmonoclonalantibodytotheepidermalgrowthfactorreceptorinthetreatmentofnonsmallcelllungcancer AT nishimuray nimotuzumabanovelmonoclonalantibodytotheepidermalgrowthfactorreceptorinthetreatmentofnonsmallcelllungcancer AT nakagawak nimotuzumabanovelmonoclonalantibodytotheepidermalgrowthfactorreceptorinthetreatmentofnonsmallcelllungcancer
_version_	1718399332902764544

Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer

Ejemplares similares